Want to see STTK full AI Analyst Report?
Top Page
Shattuck Labs
(NASDAQ:STTK)
Select Model
Select Model
Rating:53Neutral
Price Target:
$7.00
▼(-7.04% Downside)
Action:Reiterated
Date:07/16/26
The score is held back primarily by weak financial performance (large losses and ongoing cash burn on very low revenue), partially offset by a strong low-debt balance sheet. Technical indicators are supportive (price above key moving averages with positive MACD), and recent corporate updates add pipeline momentum and funding support, though dilution from the offering and loss-making status keep valuation and fundamentals pressured.
Positive Factors
Clinical Progress (SL-325)
Robust Phase 1 human data materially lowers clinical risk for SL-325 by demonstrating target engagement, durability and a clean safety signal. That increases probability of success in the planned Phase 2b Crohn’s trial, supports downstream partnering/licensing discussions, and strengthens long-term asset potential for the inflammatory franchise.
Negative Factors
Sustained Cash Burn
Persistent negative operating and free cash flow indicates ongoing reliance on external financing to sustain clinical development. While burn has improved versus prior years, the company remains far from cash-flow break-even, which creates execution risk if capital markets tighten or expected financings underperform.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Progress (SL-325)
Robust Phase 1 human data materially lowers clinical risk for SL-325 by demonstrating target engagement, durability and a clean safety signal. That increases probability of success in the planned Phase 2b Crohn’s trial, supports downstream partnering/licensing discussions, and strengthens long-term asset potential for the inflammatory franchise.
Read all positive factors
Shattuck Labs (STTK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$680.50M
Dividend YieldN/A
Average Volume (3M)1.84M
Price to Earnings (P/E)―
Beta (1Y)1.98
Revenue Growth-78.29%
EPS Growth54.16%
CountryUS
Employees40
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.63
Shares Outstanding90,372,390
10 Day Avg. Volume1,573,702
30 Day Avg. Volume1,835,642
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.08
Price to Sales (P/S)253.99
P/FCF Ratio-6.36
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$16.00Price Target Upside112.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.51
Revenue Forecast (FY)N/A
Shattuck Labs Business Overview & Revenue Model
Company Description
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company...
How the Company Makes Money
Shattuck Labs does not primarily generate revenue from product sales because its candidates are in clinical development and, to the extent publicly disclosed, it has not commercialized an approved therapy. The company’s revenue, when present, is g...
Shattuck Labs Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.00M | 1.00M | 5.72M | 1.66M | 652.00K | 30.02M |
| Gross Profit | -8.44M | -1.95M | 827.00K | -2.38M | -81.55M | 28.64M |
| EBITDA | -46.23M | -45.12M | -71.58M | -83.26M | -98.87M | -43.59M |
| Net Income | -49.87M | -48.81M | -75.41M | -87.30M | -101.94M | -44.97M |
Balance Sheet | ||||||
| Total Assets | 102.12M | 91.03M | 91.05M | 159.56M | 205.32M | 298.58M |
| Cash, Cash Equivalents and Short-Term Investments | 90.42M | 78.06M | 72.99M | 130.63M | 161.28M | 268.80M |
| Total Debt | 2.89M | 2.42M | 3.41M | 4.20M | 4.90M | 0.00 |
| Total Liabilities | 6.29M | 8.64M | 11.42M | 14.86M | 29.17M | 26.80M |
| Stockholders Equity | 95.83M | 82.39M | 79.63M | 144.71M | 176.16M | 271.79M |
Cash Flow | ||||||
| Free Cash Flow | -41.28M | -39.95M | -60.57M | -81.64M | -106.11M | -65.04M |
| Operating Cash Flow | -41.27M | -39.88M | -60.52M | -81.23M | -94.50M | -57.12M |
| Investing Cash Flow | 361.00K | -7.89M | -8.51M | 110.86M | 49.44M | -10.44M |
| Financing Cash Flow | 70.43M | 44.57M | 787.00K | 48.62M | 171.00K | 1.93M |
Shattuck Labs Technical Analysis
Positive
7.53
Price Trends
5.95
Positive
6.13
Positive
4.57
Positive
Market Momentum
0.38
Negative
64.63
Neutral
68.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STTK, the sentiment is Positive. The current price of 7.53 is above the 20-day moving average (MA) of 6.52, above the 50-day MA of 5.95, and above the 200-day MA of 4.57, indicating a bullish trend. The MACD of 0.38 indicates Negative momentum. The RSI at 64.63 is Neutral, neither overbought nor oversold. The STOCH value of 68.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STTK.
Shattuck Labs Risk Analysis
Shattuck Labs disclosed 56 risk factors in its most recent earnings report. Shattuck Labs reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Shattuck Labs Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $102.48M | -2.81 | -241.96% | ― | ― | 55.59% | |
53 Neutral | $680.50M | -11.95 | -60.73% | ― | -78.29% | 54.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $74.90M | -0.88 | -64.43% | ― | ― | 9.80% | |
47 Neutral | $58.39M | -1.61 | -117.24% | ― | 476.71% | 70.23% |
* Healthcare Sector Average
STTK
Shattuck Labs
7.53
6.76
877.92%
PYPD
PolyPid
5.37
1.62
43.20%
XLO
Xilio Therapeutics
8.88
-0.88
-9.05%
ACRV
Acrivon Therapeutics, Inc.
1.75
0.35
25.00%
Shattuck Labs Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Shattuck Labs Prices Upsized Public Equity and Warrant Offering
Positive
Jun 11, 2026
On June 9, 2026, Shattuck Labs, Inc. entered into an underwriting agreement with a syndicate of investment banks for a public offering of 10,879,376 common shares at $4.00 each and pre-funded warrants for 7,870,624 common shares at $3.9999 each. T...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Shattuck Labs Reports Promising Phase 1 Data for SL-325
Positive
Jun 9, 2026
On June 8, 2026, Shattuck Labs reported Phase 1 data for SL-325, the first DR3 receptor-blocking antibody to generate human clinical results, showing low immunogenicity, durable TL1A blockade exceeding 10 weeks, complete DR3 occupancy at low doses...
Executive/Board ChangesShareholder Meetings
Shattuck Labs Shareholders Approve Directors, Compensation, Governance Measures
Positive
Jun 2, 2026
At its recent Annual Meeting, Shattuck Labs’ shareholders elected all Class III director nominees, including Taylor Schreiber, M.D., Ph.D., Helen M. Boudreau and Clay Siegall, Ph.D., and approved all other proposals, including the ratificati...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.